Form 4: Quantum-Si CPO Awarded Significant Equity Package

Quantum-Si's Chief Product Officer, John S. Vieceli, was granted 391,681 restricted stock units and options for 468,508 shares of Class A Common Stock.

Summary

• John S. Vieceli, Chief Product Officer of Quantum-Si Inc. (QSI), acquired 391,681 Restricted Stock Units (RSUs) and options to purchase 468,508 shares of Class A Common Stock.
• The transaction date for both acquisitions was March 12, 2026.
• The RSUs represent the right to receive one share of common stock upon vesting and will vest in 16 equal quarterly installments beginning June 20, 2026, contingent on continued service.
• The stock options have an exercise price of $0.976 per share and will vest in equal quarterly installments starting June 20, 2026, also subject to continued service.
• Following these transactions, Mr. Vieceli beneficially owns 1,192,654 shares of Class A Common Stock and 468,508 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting the company's commitment to retaining key leadership and aligning executive incentives with long-term shareholder value.

Positives

• The grant of RSUs and stock options aligns the Chief Product Officer's interests with long-term shareholder value.
• The vesting schedule, tied to continued service, incentivizes executive retention and performance.

Risks

• The vesting of both RSUs and stock options is subject to Mr. Vieceli's continued service, meaning unvested portions would be forfeited upon departure.

Future Outlook

The vesting schedules for both the RSUs and stock options, commencing June 20, 2026, indicate a long-term incentive structure designed to retain the Chief Product Officer and align his performance with the company's future success over several years.

Industry Context

StockSavvy.ai notes that significant equity grants to key executives like a Chief Product Officer are a standard practice in the biotechnology and life sciences sectors, particularly for growth-oriented companies like Quantum-Si. These grants are crucial for attracting, retaining, and motivating top talent, ensuring their long-term commitment to product development and strategic goals.

Comparison to Industry Standards

• Equity compensation packages for C-suite executives in the biotech industry often include a mix of restricted stock units and stock options, similar to this grant.
• Comparable companies in the diagnostics or genomics space, such as Illumina or Pacific Biosciences, frequently utilize multi-year vesting schedules (e.g., 3-5 years) to ensure executive retention and alignment with long-term strategic objectives.
• The 16-quarter (4-year) vesting schedule for Mr. Vieceli's awards is consistent with typical industry practices aimed at fostering sustained leadership and innovation.

Stakeholder Impact

• Shareholders: The equity grant aligns the Chief Product Officer's financial interests with the long-term performance of the company, potentially benefiting shareholders through sustained leadership and strategic execution.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.

Next Steps

• The RSUs and stock options will begin vesting in 16 equal quarterly installments starting June 20, 2026.
• Mr. Vieceli must maintain continued service with Quantum-Si Inc. to receive the vested shares and exercise the options.

Key Dates

Keywords

QSI, Quantum-Si, Form 4, insider transaction, equity grant, RSU, stock option, executive compensation